Evidence map›Paper›PMID 41978641›Full record

ReviewAntibody therapeutics2026

Challenges and solutions for upstream processing of complex biologics.

Shuya Xu, Yunlong Wang, Yawen Yu, Felix Zhu, Ying Li

Abstract readReview
In one paragraph

Review in Antibody therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shuya XuDepartment of Antibody Process Development, GenScript ProBio Biotechnology Co., Ltd, Nanjing 21100, China.
Yunlong WangDepartment of Antibody Process Development, GenScript ProBio Biotechnology Co., Ltd, Nanjing 21100, China.
Yawen YuDepartment of Antibody Process Development, GenScript ProBio Biotechnology Co., Ltd, Nanjing 21100, China.
Felix ZhuDepartment of Antibody Process Development, GenScript ProBio Biotechnology Co., Ltd, Nanjing 21100, China.
Ying LiDepartment of Antibody Process Development, GenScript ProBio Biotechnology Co., Ltd, Nanjing 21100, China.ORCID https://orcid.org/0009-0006-2010-7974

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unlike conventional monoclonal antibodies, complex biologics-such as bispecific antibodies and fusion proteins-often face challenges including lower expression levels, higher mispairing rates, and greater sensitivity to culture conditions, which can collectively limit both titer and product quality. Leveraging process development case studies, this review systematically explores upstream bioprocessing strategies aimed at mitigating these challenges, with a focus on titer enhancement, lactate metabolism regulation, acidic charge variants control, reduction of aggregates and fragments, and glycosylation optimization. Finally, a perspective toward future upstream development strategies is discussed.

Indexed as

cell culturebispecific antibodyfusion proteinquality improvementtiter enhancementupstream processing

Identifiers

PMID41978641
PMCPMC13070570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.